Chimie generală Şi farmaceutică tehnologia medicamentelor în memoriam conferenţiar universitar

Bibliografie

1. 
   Bengur A. R., RH Beekman, AP Rocchini, DC Crowley, MA Schork and A Rosenthal “ Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy .“ 1991, 83, p.523-527
   
2. 
   Bouissou F, Meguire B, Rostin M, Fontaine C, Charlet JP, Barthe PH. Long term therapy by captopril in children with renal hypertension. Clin Exp Theory Pract 1986, no. 8 p.841-845.
   
3. 
   Cimpan G., Box K., Measurement of Physicochemical Parameters ADMET- turning chemicals into drugs. Nature-Biotechnology, 2001, 19, p. 722-726.
   
4. 
   Comer J., Tam K., Lipophilicity Profiles: Theory and Measurement, in Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies, E: Testa, B.; van de Waterbeemd, H.; Folkers, G.; Guy, R.; VHCA: Zurich, 2001, p. 275-304
   
5. 
   Diug Eugen, Diana Guranda. Biofarmacie şi farmacocinetică, ed. “Universul”, Chişinău, 2009, 143 p.
   
6. 
   Ferreira SH and Vane JR: The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br. J. Pharm. Chemother. 1967, 30, p. 417-424.
   
7. 
   Gauthier B, Trachtman H, Frank R, Pillari G. Inadequacy of captopril challenge test for diagnosing renovascular hypertension in children and adolescents. Pediatr Nephrol. 1991 Jan, no. 5 (1) p.42-44.
   
8. 
   Kazerani H, Hajimoradi B, Amini A, Naseri MH, Moharamzad Y. “Clinical efficacy of sublingual captopril in the treatment of hypertensive urgency”, Singapore Med J. 2009 Apr, nr. 50(4), p.400-402.
   
9. 
   Leucuţa S. Biofarmacie şi farmacocinetică, ed. Dacia, Cluj-Napoca, 2002, 304 p.
   
10. 
    Levy M, Koren G, Klein J, McLorie G, Balfe JW,”Clearance captopril children” Dev Pharmacol Ther. 1991, no. 16 (4), p.185-193.
    
11. 
    Lipinski, C. A. et al. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Deliv. Rev., 1997, 23, p. 3-25
    
12. 
    Mircioiu Constantin, Miron Dalia, Flavian Rădulescu, Ghiciuc Cristina, Mircioiu Ion. Elemente de biofarmacie şi farmacocinetică, Vol.1, Fundamente. Editura Universitară Carol Davila, Bucureşti, 2008, 190 p.
    
13. 
    Mircioiu Constantin, Miron Dalia, Flavian Rădulescu, Mircioiu Ion, Anuţa Valentina. Elemente de biofarmacie şi farmacocinetică, Vol.2, Evaluări comparative şi corelări. Editura Universitară „Carol Davila”, Bucureşti, 2008, p.136
    
14. 
    Palm, K. et al. Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans. Pharm. Res. 1997, 14, p. 568-571
    
15. 
    Sadowski RH, Falkner B. Hypertension in pediatric patients. Am J Kidney Dis 1996, no. 27 p.305-315.
    
16. 
    Sinaiko A, Kashtan CE, Mirkin BL. Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Theory Pract 1986, no. 8 p.829-39.
    
17. 
    Smith CG, Vane JR "The discovery of captopril".The FASEB Journal. 2003, no. 17, p.788-779.
    
18. 
    Solonari R., Studiul recepturii pulberilor extemporale pentru copii în farmaciile de producere din municipiul Chişinău. Revista Farmaceutică a Moldovei, 2008, nr. 1-2, p. 20-23.
    
19. 
    Vancea S, Muntean DL, Sipos E, Cociş A, Avrigeanu V, Mircia E. “Stability of some medicinal solutions with captopril” Revista medico-chirurgicala a societatii de medici si naturalişti din Iaşi. 2008. vol. 112, nr. 3.
    
20. 
    Kevin and Vane JR: Fate of angiotensin I in the circulation. Nature, 1968, 218, p. 144-150.
    
21. 
    Kevin and Vane JR: Some properties of angiotensin converting enzyme in the lung in vivo. Nature, 1970, 225, p. 1142-1144.
    
22. 
    Veber D. F., et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, vol.45, no. 12, p. 2615–26
    
23. 
    Sinaiko A, Kashtan CE, Mirkin BL. Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Theory Pract 1986, no. 8 p.829-39.